MPM Oncology Impact Management »

Guardant Health shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Guardant Health (GH) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Guardant Health

Tip: Access up to 7 years of quarterly data

All positions including Guardant Health held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Guardant Health by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $14M 500k 28.88

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Guardant Health

Vanguard Group
BlackRock
Baillie Gifford & Co
Cadian Capital Management
Deep Track Capital
Temasek Holdings
Capital Research and Management Company - Division 3
Eventide Asset Management
Citadel Advisors
FMR
Braidwell
Parkwood
Geode Capital Management
State Street Corporation
Millennium Management

View all funds holding Guardant Health